23561827|t|Celecoxib reduces brain dopaminergic neuronaldysfunction, and improves sensorimotor behavioral performance in neonatal rats exposed to systemic lipopolysaccharide.
23561827|a|BACKGROUND: Cyclooxygenase-2 (COX-2) is induced in inflammatory cells in response to cytokines and pro-inflammatory molecules, suggesting that COX-2 has a role in the inflammatory process. The objective of the current study was to examine whether celecoxib, a selective COX-2 inhibitor, could ameliorate lipopolysaccharide (LPS)-induced brain inflammation, dopaminergic neuronal dysfunction and sensorimotor behavioral impairments. METHODS: Intraperitoneal (i.p.) injection of LPS (2 mg/kg) was performed in rat pups on postnatal Day 5 (P5), and celecoxib (20 mg/kg) or vehicle was administered (i.p.) five minutes after LPS injection. Sensorimotor behavioral tests were carried out 24 h after LPS exposure, and brain injury was examined on P6. RESULTS: Our results showed that LPS exposure resulted in impairment in sensorimotor behavioral performance and injury to brain dopaminergic neurons, as indicated by loss of tyrosine hydroxylase (TH) immunoreactivity, as well as decreases in mitochondria activity in the rat brain. LPS exposure also led to increases in the expression of alpha-synuclein and dopamine transporter proteins and enhanced [3H]dopamine uptake. Treatment with celecoxib significantly reduced LPS-induced sensorimotor behavioral disturbances and dopaminergic neuronal dysfunction. Celecoxib administration significantly attenuated LPS-induced increases in the numbers of activated microglia and astrocytes and in the concentration of IL-1beta in the neonatal rat brain. The protective effect of celecoxib was also associated with an attenuation of LPS-induced COX-2+ cells, which were double labeled with TH + (dopaminergic neuron) or glial fibrillary acidic protein (GFAP) + (astrocyte) cells. CONCLUSION: Systemic LPS administration induced brain inflammatory responses in neonatal rats; these inflammatory responses included induction of COX-2 expression in TH neurons and astrocytes. Application of the COX-2 inhibitor celecoxib after LPS treatment attenuated the inflammatory response and improved LPS-induced impairment, both biochemically and behaviorally.
23561827	0	9	Celecoxib	Chemical	MESH:D000068579
23561827	24	56	dopaminergic neuronaldysfunction	Disease	MESH:D009422
23561827	119	123	rats	Species	10116
23561827	144	162	lipopolysaccharide	Chemical	MESH:D008070
23561827	176	192	Cyclooxygenase-2	Gene	29527
23561827	194	199	COX-2	Gene	29527
23561827	215	227	inflammatory	Disease	MESH:D007249
23561827	267	279	inflammatory	Disease	MESH:D007249
23561827	307	312	COX-2	Gene	29527
23561827	331	343	inflammatory	Disease	MESH:D007249
23561827	411	420	celecoxib	Chemical	MESH:D000068579
23561827	434	439	COX-2	Gene	29527
23561827	468	486	lipopolysaccharide	Chemical	MESH:D008070
23561827	488	491	LPS	Chemical	MESH:D008070
23561827	501	519	brain inflammation	Disease	MESH:D004660
23561827	521	554	dopaminergic neuronal dysfunction	Disease	MESH:D009461
23561827	572	594	behavioral impairments	Disease	MESH:D001523
23561827	641	644	LPS	Chemical	MESH:D008070
23561827	672	675	rat	Species	10116
23561827	710	719	celecoxib	Chemical	MESH:D000068579
23561827	785	788	LPS	Chemical	MESH:D008070
23561827	858	861	LPS	Chemical	MESH:D008070
23561827	876	888	brain injury	Disease	MESH:D001930
23561827	942	945	LPS	Chemical	MESH:D008070
23561827	1037	1049	dopaminergic	Disease	MESH:D009422
23561827	1083	1103	tyrosine hydroxylase	Gene	25085
23561827	1105	1107	TH	Gene	25085
23561827	1180	1183	rat	Species	10116
23561827	1191	1194	LPS	Chemical	MESH:D008070
23561827	1247	1262	alpha-synuclein	Gene	29219
23561827	1310	1322	[3H]dopamine	Chemical	-
23561827	1346	1355	celecoxib	Chemical	MESH:D000068579
23561827	1378	1381	LPS	Chemical	MESH:D008070
23561827	1403	1426	behavioral disturbances	Disease	MESH:D001523
23561827	1431	1464	dopaminergic neuronal dysfunction	Disease	MESH:D009461
23561827	1466	1475	Celecoxib	Chemical	MESH:D000068579
23561827	1516	1519	LPS	Chemical	MESH:D008070
23561827	1619	1627	IL-1beta	Gene	24494
23561827	1644	1647	rat	Species	10116
23561827	1680	1689	celecoxib	Chemical	MESH:D000068579
23561827	1733	1736	LPS	Chemical	MESH:D008070
23561827	1745	1750	COX-2	Gene	29527
23561827	1790	1792	TH	Gene	25085
23561827	1796	1808	dopaminergic	Disease	MESH:D009422
23561827	1820	1851	glial fibrillary acidic protein	Gene	24387
23561827	1853	1857	GFAP	Gene	24387
23561827	1901	1904	LPS	Chemical	MESH:D008070
23561827	1928	1946	brain inflammatory	Disease	MESH:D004660
23561827	1969	1973	rats	Species	10116
23561827	1981	1993	inflammatory	Disease	MESH:D007249
23561827	2026	2031	COX-2	Gene	29527
23561827	2046	2048	TH	Gene	25085
23561827	2092	2097	COX-2	Gene	29527
23561827	2108	2117	celecoxib	Chemical	MESH:D000068579
23561827	2124	2127	LPS	Chemical	MESH:D008070
23561827	2153	2165	inflammatory	Disease	MESH:D007249
23561827	2188	2191	LPS	Chemical	MESH:D008070
23561827	Positive_Correlation	MESH:D008070	29527
23561827	Association	MESH:D007249	25085
23561827	Association	MESH:D009422	29527
23561827	Association	25085	29527
23561827	Negative_Correlation	MESH:D000068579	MESH:D004660
23561827	Positive_Correlation	MESH:D008070	MESH:D009461
23561827	Negative_Correlation	MESH:D008070	25085
23561827	Negative_Correlation	MESH:D000068579	MESH:D008070
23561827	Positive_Correlation	MESH:D008070	29219
23561827	Association	MESH:D004660	29527
23561827	Positive_Correlation	MESH:D008070	24494
23561827	Negative_Correlation	MESH:D000068579	MESH:D009422
23561827	Negative_Correlation	MESH:D000068579	MESH:D001523
23561827	Positive_Correlation	MESH:D008070	MESH:D004660
23561827	Association	MESH:D008070	MESH:D009422
23561827	Association	MESH:D007249	29527
23561827	Association	MESH:D008070	24387
23561827	Negative_Correlation	MESH:D000068579	MESH:D009461
23561827	Negative_Correlation	MESH:D000068579	24494
23561827	Association	MESH:D009422	25085
23561827	Negative_Correlation	MESH:D000068579	29527
23561827	Positive_Correlation	MESH:D008070	MESH:D001523

